Development of a RNA-seq based prognostic signature in lung adenocarcinoma

Journal of the National Cancer Institute

Volumn 109, Issue 1, 2017, Pages

  Shukla, Sudhanshu ^a,b   Evans, Joseph R ^c   Malik, Rohit ^a,b   Feng, Felix Y ^b,c,d   Dhanasekaran, Saravana M ^a,b   Cao, Xuhong ^a,b   Chen, Guoan ^e   Beer, David G ^e   Jiang, Hui ^c   Chinnaiyan, Arul M ^a,b,c,f  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c Department of Radiation Oncology ^*  (United States)

^d Department of Pharmacology and Toxicology and Mass Spectrometry Core Facility   (United States)

^e Section of Thoracic Surgery   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; LONG UNTRANSLATED RNA; CD109 PROTEIN, HUMAN; FRRS1L PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; NERVE PROTEIN; RHOV PROTEIN, HUMAN; TRANSCRIPTOME; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; MUTANT; OVERALL SURVIVAL; PRIORITY JOURNAL; RNA SEQUENCE; WILD TYPE; ADENOCARCINOMA; GENETIC DATABASE; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SECONDARY; SEQUENCE ANALYSIS; SURVIVAL RATE; VALIDATION STUDY;

ADENOCARCINOMA; AGED; ANTIGENS, CD; DATABASES, GENETIC; FEMALE; GPI-LINKED PROTEINS; GTP-BINDING PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; NEOPLASM STAGING; NERVE TISSUE PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SEQUENCE ANALYSIS, RNA; SURVIVAL RATE; TRANSCRIPTOME;

EID: 85014874086     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw200     Document Type: Article

References (45)

1. Cancer Facts & Figures 2015. In: Atlanta, GA: American Cancer Society; 2015.
2. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12(2):175-180.
3. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2(8):706-714.
4. Ten Haaf K, van Rosmalen J, de Koning HJ. Lung cancer detectability by test, histology, stage, and gender: Estimates from the NLST and the PLCO trials. Cancer Epidemiol Biomarkers Prev. 2015;24(1):154-161.
5. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002;8(8):816-824.
6. Zhu CQ, Tsao MS. Prognostic markers in lung cancer: Is it ready for prime time? Transl Lung Cancer Res. 2014;3(3):149-158.
7. Starmans MH, Pintilie M, Chan-Seng-Yue M, et al. Integrating RAS status into prognostic signatures for adenocarcinomas of the lung. Clin Cancer Res. 2015; 21(6):1477-1486.
8. Zheng Y, Bueno R. Commercially available prognostic molecular models in early-stage lung cancer: A review of the Pervenio Lung RS and Myriad myPlan Lung Cancer tests. Expert Rev Mol Diagn. 2015;15(5):589-596.
9. Iyer MK, Niknafs YS, Malik R, et al. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 2015;47(3):199-208.
10. Prensner JR, Zhao S, Erho N, et al. RNA biomarkers associated with metastatic progression in prostate cancer: A multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol. 2014;15(13):1469-1480.
11. Damodaran S, Berger MF, Roychowdhury S. Clinical tumor sequencing: Opportunities and challenges for precision cancer medicine. Am Soc Clin Oncol Educ Book. 2015;35:e175-e182.
12. Cieslik M, Chugh R,Wu YM, et al. The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing. Genome Res. 2015; 25:1372-1381.
13. Balbin OA, Malik R, Dhanasekaran SM, et al. The landscape of antisense gene expression in human cancers. Genome Res. 2015;25(7):1068-1079.
14. Kim D, Pertea G, Trapnell C, et al. TopHat2: Accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14(4):R36.
15. Flicek P, Ahmed I, Amode MR, et al. Ensembl 2013. Nucleic Acids Res. 2013; 41(Database issue):D48-D55.
16. Dhanasekaran SM, Balbin OA, Chen G, et al. Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. Nat Commun. 2014;5:5893.
17. Torres-Garcia W, Zheng S, Sivachenko A, et al. PRADA: Pipeline for RNA sequencing data analysis. Bioinformatics. 2014;30(15):2224-2226.
18. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9(2):166-180.
19. Mi H, Muruganujan A, Thomas PD. PANTHER in 2013: Modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res. 2013;41(Database issue):D377-D386.
20. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550.
21. Boutros PC, Lau SK, Pintilie M, et al. Prognostic gene signatures for nonsmall-cell lung cancer. Proc Natl Acad Sci U S A. 2009;106(8):2824-2828.
22. Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007;356(1):11-20.
23. Kratz JR, Van den Eeden SK, He J, et al. A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors. JAMA. 2012;308(16):1629-1631.
24. Bianchi F, Nuciforo P, Vecchi M, et al. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest. 2007;117(11):3436-3444.
25. Lau SK, Boutros PC, Pintilie M, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol. 2007;25(35): 5562-5569.
26. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21): 3552-3559.
27. Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008;26(31):5043-5051.
28. Kratz JR, Mann MJ, Jablons DM. International trial of adjuvant therapy in high risk stage I non-squamous cell carcinoma identified by a 14-gene prognostic signature. Transl Lung Cancer Res. 2013;2(3):222-225.
29. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139.
30. Goss GD, O'Callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: Results of the NCIC CTG BR19 study. J Clin Oncol. 2013;31(27):3320-3326.
31. Kelly K, Altorki NK, Eberhardt WEE, et al. A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results. J Clin Oncol. 2014;32(15-suppl):7501.
32. Gerber DE, Oxnard GR, Govindan R. ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer. Clin Pharmacol Ther. 2015; 97(5):447-450.
33. Consortium EP, Birney E, Stamatoyannopoulos JA, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007;447(7146):799-816.
34. Febbo PG, Kantoff PW. Noise and bias in microarray analysis of tumor specimens. J Clin Oncol. 2006;24(23):3719-3721.
35. Robinson DG, Wang JY, Storey JD. A nested parallel experiment demonstrates differences in intensity-dependence between RNA-seq and microarrays. Nucleic Acids Res. 2015;43(20):e131.
36. Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med 2014;20(12):1479-84.
37. Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543-550.
38. Saal LH, Vallon-Christersson J, Hakkinen J, et al. The Sweden Cancerome Analysis Network-Breast (SCAN-B) Initiative: A large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Med. 2015;7(1):20.
39. Bizet AA, Tran-Khanh N, Saksena A, et al. CD109-mediated degradation of TGF-beta receptors and inhibition of TGF-beta responses involve regulation of SMAD7 and Smurf2 localization and function. J Cell Biochem. 2012;113(1): 238-246.
40. Tao J, Li H, Li Q, et al. CD109 is a potential target for triple-negative breast cancer. Tumour Biol. 2014;35(12):12083-12090.
41. Haun RS, Fan CY, Mackintosh SG, et al. CD109 overexpression in pancreatic cancer identified by cell-surface glycoprotein capture. J Proteomics Bioinform. 2014;Suppl 10:S10003.
42. Shepelev MV, Korobko IV. The RHOV gene is overexpressed in human nonsmall cell lung cancer. Cancer Genet. 2013;206(11):393-397.
43. Vargas JD, Herpers B, McKie AT, et al. Stromal cell-derived receptor 2 and cytochrome b561 are functional ferric reductases. Biochim Biophys Acta. 2003; 1651(1-2):116-123.
44. Jin Y, Wang L, Qu S, et al. STAMP2 increases oxidative stress and is critical for prostate cancer. EMBO Mol Med. 2015;7(3):315-331.
45. Derrien T, Johnson R, Bussotti G, et al. The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression. Genome Res. 2012;22(9):1775-1789.